Non-Hodgkin lymphoma Posts on Medivizor
Navigation Menu

Non-Hodgkin lymphoma Posts on Medivizor

Evaluating zanubrutinib combined with obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma

Evaluating zanubrutinib combined with obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma

Posted by on Nov 2, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the combination of zanubrutinib (Brukinsa) and obinutuzumab (Gazyva) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and follicular lymphoma (FL). This study concluded that this combination was well tolerated and had promising responses in these patients.  Some...

Read More

Second stem cell transplant using reduced intensity conditioning for leukemia or lymphoma

Second stem cell transplant using reduced intensity conditioning for leukemia or lymphoma

Posted by on Oct 25, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the outcomes of a second hematopoietic stem cell transplant (HSCT) after reduced-intensity conditioning (RIC) for patients with leukemia or lymphoma.   This study concluded that this treatment path is feasible and a good treatment alternative for these patients.   Some background Allogenic...

Read More

R-CHOP is associated with an increased risk of fractures in older patients with diffuse large B-cell lymphoma.

R-CHOP is associated with an increased risk of fractures in older patients with diffuse large B-cell lymphoma.

Posted by on Oct 18, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study was carried out to assess the risk of fractures associated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) for diffuse large B-cell lymphoma (DLBCL). The authors found that there was a high fracture risk in older patients receiving R-CHOP for the treatment of...

Read More

How the characteristics of CAR-T cell infusion products impact their effectiveness and toxicity in patients with large B cell lymphomas

How the characteristics of CAR-T cell infusion products impact their effectiveness and toxicity in patients with large B cell lymphomas

Posted by on Oct 18, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study evaluated how characteristics of CAR-T cell infusion (CTCI) products impact their effectiveness and toxicity in patients with large B cell lymphoma (LBCL). The authors found that diversity in molecular and cellular features of CTCI products caused variations in efficacy and toxicity after axicabtagene-ciloleucel (axi-cel;...

Read More

Seeking patients with relapsed B-cell NHL or CLL for trial of kinase-blocking treatment

Seeking patients with relapsed B-cell NHL or CLL for trial of kinase-blocking treatment

Posted by on Oct 11, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study will evaluate a three-drug regimen for the treatment of relapsed B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL). The primary outcomes are how many patients respond to treatment or have a complete response (cancer no longer detectable). The study will take place in the United States. The details B-cell...

Read More

Looking for participants to test an experimental immunotherapy for relapsed non-Hodgkin lymphoma

Looking for participants to test an experimental immunotherapy for relapsed non-Hodgkin lymphoma

Posted by on Oct 11, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study will evaluate the antibody therapy odronextamab for patients with relapsed B-cell non-Hodgkin lymphoma (NHL). The primary outcomes will be how many patients respond to treatment, and how many have a complete response (cancer no longer detectable).  The details For B-cell NHL which has relapsed (returned) after...

Read More

Evaluating 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

Evaluating 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

Posted by on Oct 4, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study evaluated the safety and effectiveness of 177Lu-lilotomab satetraxetan (177LLS; Betalutin) in patients with relapsed/refractory (r/r) indolent non-Hodgkin lymphoma (iNHL). The main finding was that 177LLS was proven to be a valuable alternative treatment in such patients. Some background NHL is a type of lymphoma that spreads...

Read More

Total body irradiation and risk of breast cancer after transplantation in patients with leukemia-lymphoma

Total body irradiation and risk of breast cancer after transplantation in patients with leukemia-lymphoma

Posted by on Oct 3, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the association between total body irradiation and further breast cancer diagnosis in patients treated with blood or marrow transplantation for leukemia-lymphoma.  This study concluded that there is an association between the total body irradiation and an increased risk of breast cancer in certain...

Read More